newsfilter
← Latest News
PR Newswire·

UCB Showcases Key Rheumatology Data at ACR Convergence 2021

ATLANTA, Nov. 5, 2021 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced new data on its investigational IL-17A and IL-17F inhibitor, bimekizumab, and its TNF inhibitor, CIMZIA® (certolizumab pegol). Eleven abstracts are being pre